secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2023-12-15T23:59:59+00:00
Accession:  0001654954-23-015629
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech FY2023 net loss $8.4M ($2.93/sh); secures C$23M govt funding for Phase 3 ARDS trial
--------------------------------------------------------------------------------

- Net loss narrowed to $8.4M ($2.93 per share) from $17.6M ($8.37) in FY2022; R&D expenses fell to $4.8M from $13.3M.
- Canadian government committed up to C$23M (partially repayable) for Phase 3 study of ARDS drug EB05 (paridiprubart); FDA Fast Track granted.
- Established $10M revolving credit facility; cash and equivalents $5.4M at Sept 30, 2023, with $0.3M raised post-year-end via equity distribution.
- Plans to initiate Phase 2 trial for vitiligo drug EB06 (anti-CXCL10) and file IND for fibrotic diseases; evaluating partnership for dermatitis drug EB01 after positive Phase 2b.
- Management to present at Dermatology Summit and JP Morgan week in January 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/0001654954-23-015629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423015629/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-015629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer